A Double-Blind, Randomized, Three-arm, Active-Controlled, Parallel-Group, Phase 1 Study Evaluating Pharmacokinetic Similarity of Three Formulations of Pembrolizumab (CT-P51, EU-approved Keytruda, and US-licensed Keytruda) as Adjuvant Therapy in Patients with Completely Resected Stage IIB, IIC, and III Melanoma
CT-P51 1.1
Phase 1 other active
Quick answer
A Double-Blind, Randomized, Three-arm, Active-Controlled, Parallel-Group, Phase 1 Study Evaluating Pharmacokinetic Similarity of Three Formulations of Pembrolizumab (CT-P51, EU-approved Keytruda, and US-licensed Keytruda) as Adjuvant Therapy in Patients with Completely Resected Stage IIB, IIC, and III Melanoma for Completely Resected Stage IIB, IIC, and III Melanoma is a Phase 1 program (other) at Celltrion Healthcare Hungary Kft. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Celltrion Healthcare Hungary Kft.
- Indication
- Completely Resected Stage IIB, IIC, and III Melanoma
- Phase
- Phase 1
- Modality
- other
- Status
- active